ICES is the third tier of the MISTIE phase-II trial. In this tier, intraventricular hemorrhage patients underwent stereotactic-guided endoscopic evacuation rather than thrombolysis. All other aspects of the trial, including the 6-month and 12-month neurological outcome assessments, are identical, allowing a comparison between endoscopic evaluation, pharmacologic therapy and standard medical care. The Surgical Coordinating Center for ICES was at the University of California Los Angeles (UCLA), under the direction of Principal Investigator Dr. Paul Vespa. Enrollment in the ICES tier is closed. The last of 18 enrolled endoscopy patients completed the 12-month follow-up in April-2013. Results will be published soon.

ClinicalTrials.gov Identifier: